# Celliaz selects Andelyn to develop and manufacture retinal gene therapy

_Published Thursday, November 12, 2026 at 12:08 PM EST · Science · Latest · Tier 2 — Notable_

![Celliaz selects Andelyn to develop and manufacture retinal gene therapy — Primary](https://s.yimg.com/lo/mysterio/api/75b6673ee79614483bb36c524761c21852b28106a7b607fe69c9eff0e9a440f7/lightyear_networkapi/resizefill_w1200%3Bquality_80%3Bformat_webp/https%3A%2F%2Fmedia.zenfs.com%2Fen%2Fprnewswire.com%2F095fafea48c88c95f07527408d3515d8.jpg)

Andelyn Biosciences and Celliaz announced a partnership to develop and manufacture CLZ002, an investigational gene therapy for retinitis pigmentosa. Andelyn will provide plasmid and AAV2 viral-vector manufacturing through its Curator Suspension Platform, supporting studies needed for an investigational new drug application and a planned Phase 1/2 trial.

Celliaz says the therapy aims to restore retinal regeneration by preventing the protein PROX1 from transferring into Müller glia, retinal cells with latent regenerative potential. The approach targets a regeneration mechanism rather than individual disease-causing mutations; clinical testing remains planned.

## Sources

- [Yahoo Finance](https://finance.yahoo.com/healthcare/articles/andelyn-biosciences-develop-manufacture-aav-150600896.html)

---
Canonical: https://techandbusiness.org/newswire/J6q3m64_98MhxuvEhGZaUs
Published: 2026-11-12T17:08:43.213Z
Story chronology: 2026-11-12T15:06:00.000Z
Retrieved: 2026-11-12T19:01:01.748Z
Publisher: Tech & Business (techandbusiness.org)